Last reviewed · How we verify
Lenalidomide/Low dose Dex
Lenalidomide enhances immune cell proliferation and anti-tumor activity while dexamethasone provides anti-inflammatory and anti-myeloma effects.
Lenalidomide enhances immune cell proliferation and anti-tumor activity while dexamethasone provides anti-inflammatory and anti-myeloma effects. Used for Multiple myeloma (newly diagnosed and relapsed/refractory).
At a glance
| Generic name | Lenalidomide/Low dose Dex |
|---|---|
| Sponsor | King Faisal Specialist Hospital & Research Center |
| Drug class | Immunomodulatory agent + corticosteroid combination |
| Target | Cereblon (CRBN), TNF-α pathway, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenalidomide is an immunomodulatory agent that enhances T-cell and natural killer cell proliferation, increases IL-2 and IFN-γ production, and has direct anti-proliferative effects on myeloma cells. Low-dose dexamethasone is a corticosteroid that provides additional anti-inflammatory activity and enhances the cytotoxic effects of lenalidomide against malignant plasma cells. This combination is synergistic in multiple myeloma treatment.
Approved indications
- Multiple myeloma (newly diagnosed and relapsed/refractory)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Constipation
- Neuropathy
- Infection
- Hyperglycemia
Key clinical trials
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma (PHASE1)
- Selinexor and Backbone Treatments of Multiple Myeloma Patients (PHASE1, PHASE2)
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma (PHASE3)
- Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (PHASE2)
- Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (PHASE2)
- Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma (PHASE1)
- A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: